Indication · Psychosis Associated With Alzheimer's Disease

Psychosis Associated With Alzheimer's Disease FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 2 Psychosis Associated With Alzheimer's Disease drugs. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
karxt (BMS-986510)BMY——
ML-007C-MAMPLT——

Upcoming catalysts

DateDrugCompanyEventIndicationStatusSource
Oct 2026 to Jan 2027Quarter disclosedkarxt (BMS-986510)BMYTopline readoutPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
Dec 2026 to Mar 2027Quarter disclosedkarxt (BMS-986510)BMYTopline readoutPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
December 2026Month disclosedkarxt (BMS-986510)BMYPrimary completionPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2027Quarter disclosedkarxt (BMS-986510)BMYTopline readoutPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
September 2027Month disclosedkarxt (BMS-986510)BMYPrimary completionPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
December 2027Month disclosedML-007C-MAMPLTPrimary completionPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
Dec 2027 to Mar 2028Quarter disclosedML-007C-MAMPLTTopline readoutPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
March 2029Month disclosedML-007C-MAMPLTPrimary completionPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedML-007C-MAMPLTTopline readoutPsychosis Associated With Alzheimer's DiseaseScheduledClinicalTrials.gov

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
October 2026Month disclosedkarxt (BMS-986510)BMYPrimary completionPsychosis Associated With Alzheimer's DiseaseDelayedClinicalTrials.gov

All indications · Approval rates by indication

Questions

What Psychosis Associated With Alzheimer's Disease drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.